Abstract P1-01-26: Clinical Implications of pN0 mol+ in Breast Cancer Patients
Catalina Falo(Institut d'Investigació Biomédica de Bellvitge), AP. Escobedo(Bellvitge University Hospital), Antonio Moreno(Universitat Autònoma de Barcelona), Idoia Morilla(Institut d'Investigació Biomédica de Bellvitge), Aileen I. Fernandez(Yale University), Anna Gumà(Bellvitge University Hospital), Enric Benito(Bellvitge University Hospital), J.M. Serra(Bellvitge University Hospital), Mar Varela(Bellvitge University Hospital)
Cited by 0
Related Papers
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
|JAMA Oncology|2022|347
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer
|Modern Pathology|2021|166
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
|Laboratory Investigation|2022|141
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
|Modern Pathology|2023|98
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
|Journal of Thoracic Oncology|2022|40